Market Overview

Vetr Crowd Doesn't Like Outlook For Clovis Oncology


On Wednesday, the Vetr crowd downgraded their rating for Clovis Oncology Inc (NASDAQ: CLVS) from 3 stars (Hold) to 2.5 stars (Sell). Sentiment of the stock among Vetr users is also down, with 85 percent of crowd ratings bearish.

Like most companies in the biotech sector, shares of the cancer treatment biopharmaceutical company saw a hefty 34 percent bump following the election, cresting at $36.70 last week. The stock traded recently at $36.12.

However, a reported Q3 loss of $1.70 per share as well as questions of efficacy and potential health risks surrounding the launch of rucaparib, Clovis Oncology's new ovarian cancer treatment medication, has created a some anxiety among investors.

See how crowdsourced ratings can help you time the market.

The Vetr Crowd’s average target price is down at $33.59, which is below the average analyst target price of $37.82. Less than 2 percent of Vetr users are holding CLVS in their watch lists.

Posted-In: VetrDowngrades Crowdsourcing Analyst Ratings General


Related Articles (CLVS)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Seeing Uncertainty, Vetr Drops U.S. Steel

Todd Gordon's Guggenheim CurrencyShares Euro Trust Trade